Benzinga is an innovative financial news outlet that has become the first choice for brokerages given its easy-to-integrate API suite and easy-to-consume content. Benzinga provides timely, actionable ...

With the Federal Reserve potentially cutting interest rates for the first time in over four years, uncertainty looms in the ...

Whether you are looking for dividend income, high growth, or something in between, there are ETFs for you. Here are three of the best that money can buy, and you can own shares in all three for less ...

The Phase II results bolster the firm's confidence in the c-MET expression cutoff it has established in an ongoing Phase III trial of the drug.

Image Source: Zacks Investment Research The targeted market in the IBD space is highly competitive. A key player in this ...

The healthcare industry is thriving, owing to the growing healthcare expenditure and aging population. Given the industry’s ...

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks ...

AbbVie Inc . (NYSE:ABBV) Executive Chairman of the Board, Richard A. Gonzalez, has recently sold a significant number of shares in the company. According to the latest filings, ...

AbbVie Inc. (NYSE:ABBV), a global biopharmaceutical company, develops and sells prescription medications for various health conditions, focusing on chronic autoimmune diseases, oncology ...

AbbVie (ABBV) ended the recent trading session at $197.69, demonstrating a +0.7% swing from the preceding day's closing price. This move outpaced the S&P 500's daily loss of 2.12%. At the same ...

“He’s sitting down at Mar-a-Lago after he got elected president, and this was his exact quote, he’s talking to a bunch of folks at Mar-a-Lago: ‘You’re rich as hell, and we’re gonna give you a tax cut.

In this article, we are going to take a look at where AbbVie Inc (NYSE:ABBV) stands against the other 52-week high stocks. The U.S. stock market has been on a roll, with major indices clocking ...